Erbitux (cetuximab)

P1/2, N=29, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting

P2/3, N=220, Not yet recruiting, Shanghai 10th People's Hospital

Moreover, hypokalemia was linked to improved disease control. These results provide incremental evidence regarding the clinical relevance of electrolyte disturbances, particularly hypokalemia, and highlight the need for prospective studies to clarify their prognostic and predictive significance.

In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study.

P2, N=41, Completed, Fudan University | Active, not recruiting --> Completed

Currently, NIR-PIT is approved only in Japan for the treatment of unresectable, locally recurrent head and neck squamous cell carcinoma, using the anti-epidermal growth factor receptor antibody cetuximab and the photoabsorber IR700...After confirming the absence of tumor recurrence, the patient was successfully treated using a well-vascularized pedicled flap. This case highlights two key management considerations for NIR-PIT-induced skin injury: surgical indications and cancer treatment. Further studies are necessary to improve the management of severe skin complications following NIR-PIT.

Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial...This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.

P2, N=49, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P1, N=681, Recruiting, Astellas Pharma Inc | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Dec 2028

In contrast, in patient-derived xenograft (PDX) models, eNK cells demonstrated modest tumor growth inhibition (28% reduction) as monotherapy and significantly enhanced efficacy (53% inhibition) in combination with cetuximab via antibody-dependent cellular cytotoxicity. In treated PDX tumors, human CD45-positive cells were detected within the tumor parenchyma, supporting intratumoral presence of administered human cells.These findings support the potential contribution of the five-gene modifications in enhancing tumor homing, persistence, and cytotoxicity in solid tumor treatment. This study underscores the potential of eNK cells as a novel, "off-the-shelf" allogeneic therapy for refractory solid tumors, including lung cancer.

P2, N=134, Not yet recruiting, Fudan University

P2, N=130, Recruiting, Merck Sharp & Dohme LLC